| Name | TRAF6 Peptide trifluoroacetate salt |
|---|---|
| Synonyms |
L-Lysine, L-alanyl-L-alanyl-L-valyl-L-alanyl-L-leucyl-L-leucyl-L-prolyl-L-alanyl-L-valyl-L-leucyl-L-leucyl-L-alanyl-L-leucyl-L-leucyl-L-alanyl-L-prolyl-L-α-glutamyl-L-seryl-L-alanyl-L-serylglycyl- L-prolyl-L-seryl-L-α-glutamyl-L-α-aspartyl-L-prolyl-L-seryl-L-valyl-L-asparaginyl-L-phenylalanyl-L-leucyl-
L-Alanyl-L-alanyl-L-valyl-L-alanyl-L-leucyl-L-leucyl-L-prolyl-L-alanyl-L-valyl-L-leucyl-L-leucyl-L-alanyl-L-leucyl-L-leucyl-L-alanyl-L-prolyl-L-α-glutamyl-L-seryl-L-alanyl-L-serylglycyl-L-prolyl-L -seryl-L-α-glutamyl-L-α-aspartyl-L-prolyl-L-seryl-L-valyl-L-asparaginyl-L-phenylalanyl-L-leucyl-L-lysine |
| Description | TRAF6 peptide is a specific TRAF6-p62 inhibitor. TRAF6 peptide potently abrogates NGF-dependent TrkA ubiquitination. TRAF6 peptide has good research potential in neurological diseases such as alzheimer's disease (AD), parkinson's, ALS, head trauma, epilepsy and stroke[1]. |
|---|---|
| Related Catalog | |
| In Vitro | TRAF6 peptide (150 µM; 5 h) blocks the interaction of p62 with TRAF6 in PC12 cells[1]. TRAF6 peptide eliminates TRAF6 and UbcH7 from interacting with TrkA and can ffectively abolish NGF-dependent ubiquitination of TrkA in vitro[1]. Western Blot Analysis[1] Cell Line: PC12 cells Concentration: 150 µM Incubation Time: 5 h Result: Inhibited the interaction of p62 with TRAF6 by immunoprecipitating TRA F6. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 2698.5±65.0 °C at 760 mmHg |
| Molecular Formula | C145H238N34O44 |
| Molecular Weight | 3161.643 |
| Flash Point | 1585.8±34.3 °C |
| Exact Mass | 3159.743164 |
| LogP | 5.04 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.556 |